🕃 Washington University in St.Louis • School of Medicine

5th INTERNATIONAL OTTAWA HEART CONFERENCE 30-31 March 2017, Ottawa, Canada

Impaired Interstitial HDL Transit in Psoriasis: an Immunological Clue in Atherosclerosis

Li-Hao "Paul" Huang Gwen Randolph Lab Department of Pathology and Immunology Washington University in St. Louis

I have no disclosure.

Macrophage Content:



Huang et al; 2015 Front. Pharmacol.

Lymphatic Vasculature



- 1. Fluid homeostasis.
- 2. Lipid absorption in gut.
- 3. Transport of immune cells.



Alitalo et al; 2011 Nature Medicine

Alitalo et al; 2005 Nature



HDL passage through tissue is a black box.....



Huang et al; 2015 Front. Pharmacol.

Schematic Models of the Interstitium and the Exclusion Phenomenon



Joseph M. Rutkowski, Melody A. Swartz. Trends Cell Biology, 2007.



Helge Wiig, and Melody A. Swartz Physiol Rev 2012

Current Gold Standard for Studies on How HDL Moves out of Tissues



- Good way to study requirements in macrophages.
- Limited to peritoneal cavity.
- Does not assess how local changes in a tissue might influence HDL trafficking dynamics.

A New Tool to Follow Molecular Export from Tissue to Plasma...





- In vitro, PGA1 accepts cholesterol like native HDL
- Linear photoactivation in the presence of 405 nm laser light

Model is simulated by Dr. Mary Sorci-Thomas and Dr. Michael Thomas

PGA1 HDL Can be Reconstituted in Vivo





Photo-activated PGA1 in Skin Can be Detected in Plasma



Fluorescence Intensity

Cardiovascular co-morbility of psoriasis is prevalent and unexplained

Environment Stress Microorganisms Drugs

Trigger

Trauma



CXCL1

CXCL3

B-defensin 1

IMQ Application Displays Systemic Effects

IMQ : daily x 14



Remote Skin Increases mRNA for Psoriasis-linked Cytokines



HDL Does Not Efficiently Transit through Skin in the IMQ Model of Psoriasis



Why HDL Transport is Blocked?



Since lymphatic flow does not alter completely, is that the interstitium (eg., extracellular matrix modification) that accounts for impaired flux?

A Bead-based Method to Quantify Lymphatic Flow





In collaboration with Brian Sounders and Bernd Zinselmeyer

IMQ Application Systemically Increases Collagen Deposition in Skin



Depletion of CD4⁺ T cells reverses collagen accumulation and defective HDL trafficking in skin



Plasma

Insoluble Collagen



Skin Interstitial Fluid



Collagen Accumulation Blocks HDL Transport in a CD4⁺ T Cell Dependent Manner



Depletion of CD4+ T cells reverses IMQ-enhanced atherosclerosis



Generation of PGA1 Knock-in mouse



4hr post photoactivation





In collaboration with GEiC core at Wash U

HDL Cycle



The TLR7 Agonist IMQ Induces a Systemic and Sustained Accumulation of Collagen in Multiple Organs - is HDL Trafficking Impaired in All of Them?



We Can Now Detect and Quantify HDL Trafficking from the Artery Wall!



Conclusions:

To appreciate the importance of HDL transport through tissues, how it can be modulated by immunological responses, and its link to atherosclerosis...

- Two tools include a knock-in mouse line and AAV vectors of the fusion protein to monitor HDL transport through tissues.
- HDL becomes trapped in collagen-rich skin that arises in a model of psoriasis and HDL entrapment can be reversed by depletion of CD4⁺ T cells.
- HDL transport through artery wall can be monitored.





<u>University of Bergen, Norway</u> Helge Wiig

Medical College Wisconsin Mary Sorci-Thomas Mike Thomas

University of Chicago Melody Swartz

Washington University Brian Kim

Washington University (GEiC core) Shondra Miller Mike White



NIH T32 training grant: AG046743

Interesting Questions:

- How collagen deposition in artery/adventitia affects HDL transport?
- How is HDL transport in artery regulated by immune cells/TLO?
- Does HDL transport from the lesser curvature region differ from other regions?
- Why multiple CETP inhibitors fail in clinical trials?

2P-imaging of the vascular system



80µm

cCD11c-YFP DyLight 594-Lectin

00:00 [min:sec] Collagen DyLight 488-Lectin YFP Lectin 488 sub q Lectin 594 i.v. 2nd SHG



Forward and Reverse Cholesterol Transport



HEALTHCARE

Merck & Co., Inc. (MRK) CETP Inhibitor Has Low Chances Of Success

Merck's CETP inhibitor seems to have very low chances of success after Eli Lilly's similar drug failed in its late stages



Zanoni et al; 2016 Science; Keene et al; 2014 BMJ; Voight et al; 2012 The Lancet; Gursky et al; 2013 JLR. Barter et al; 2014 N. Engl. J. Med; Schwartz et al; 2012 N. Engl. Med; Keene et al; 2014 BMJ.